DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Iterum Therapeutics plc and Encourages Investors to Contact the Firm
04 oct. 2021 11h05 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against...
FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Iterum Therapeutics plc Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ITRM
03 oct. 2021 10h00 HE
|
The Rosen Law Firm PA
NEW YORK, Oct. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
ROSEN, A LEADING LAW FIRM, Encourages Iterum Therapeutics plc Investors to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ITRM
23 sept. 2021 16h48 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Iterum Therapeutics plc Investors to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ITRM
06 sept. 2021 06h12 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 06, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Iterum Therapeutics plc Investors With Losses Over $100K to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ITRM
30 août 2021 17h00 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
Iterum Therapeutics Reports First Quarter 2020 Financial Results
14 mai 2020 06h45 HE
|
Iterum Therapeutics plc
--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing investors -- DUBLIN,...
Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)
31 mars 2020 07h00 HE
|
Iterum Therapeutics plc
Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics maintaining business operations amid COVID-19 public health crisis DUBLIN, Ireland and CHICAGO,...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
12 mars 2020 06h45 HE
|
Iterum Therapeutics plc
--Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 ...
Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
19 févr. 2020 07h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection
26 déc. 2019 17h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...